scholarly article | Q13442814 |
P356 | DOI | 10.1006/JMCC.1998.0848 |
P698 | PubMed publication ID | 10072717 |
P2093 | author name string | Huang H | |
Chan J | |||
Chandra M | |||
Weiss LM | |||
Wittner M | |||
Bacchi CJ | |||
Morris SA | |||
Tanowitz HB | |||
Factor SM | |||
Jelicks LA | |||
Shirani J | |||
Braunstein VL | |||
Yarlett N | |||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Trypanosoma cruzi | Q150162 |
P304 | page(s) | 75-88 | |
P577 | publication date | 1999-01-01 | |
P1433 | published in | Journal of Molecular and Cellular Cardiology | Q2061932 |
P1476 | title | Expression of cardiac cytokines and inducible form of nitric oxide synthase (NOS2) in Trypanosoma cruzi-infected mice | |
P478 | volume | 31 |
Q35171553 | A formidable challenge: the diagnosis and treatment of viral myocarditis in children |
Q37241027 | A magnetic resonance imaging study of intestinal dilation in Trypanosoma cruzi-infected mice deficient in nitric oxide synthase |
Q24682637 | Activation of Transcription Factors AP-1 and NF-κB in Murine Chagasic Myocarditis |
Q36565590 | Advances in imaging of animal models of Chagas disease |
Q36651918 | Alterations in glucose homeostasis in a murine model of Chagas disease. |
Q38526096 | Alterations in myocardial gene expression associated with experimental Trypanosoma cruzi infection |
Q33828299 | Aspirin treatment of mice infected with Trypanosoma cruzi and implications for the pathogenesis of Chagas disease |
Q58846248 | Atrial natriuretic factor as marker of myocardial compromise in Chagas' disease |
Q26866224 | Bioactive lipids in Trypanosoma cruzi infection |
Q33317597 | Bone marrow cell therapy ameliorates and reverses chagasic cardiomyopathy in a mouse model |
Q59387726 | CD4 Th1 but not Th2 clones efficiently activate macrophages to eliminate Trypanosoma cruzi through a nitric oxide dependent mechanism |
Q44189047 | Cardioprotective effects of phosphoramidon on myocardial structure and function in murine Chagas' disease |
Q43689492 | Cardioprotective effects of verapamil on myocardial structure and function in a murine model of chronic Trypanosoma cruzi infection (Brazil Strain): an echocardiographic study |
Q34456390 | Caspase-1/ASC inflammasome-mediated activation of IL-1β-ROS-NF-κB pathway for control of Trypanosoma cruzi replication and survival is dispensable in NLRP3-/- macrophages |
Q34669016 | Cell-specific activation of nuclear factor-kappaB by the parasite Trypanosoma cruzi promotes resistance to intracellular infection |
Q35745413 | Chagas heart disease: report on recent developments |
Q33687299 | Coronary microvascular disease in chronic Chagas cardiomyopathy including an overview on history, pathology, and other proposed pathogenic mechanisms. |
Q34101524 | Crucial role of the central leptin receptor in murine Trypanosoma cruzi (Brazil strain) infection |
Q35987379 | Current status of cardiac MRI in small animals. |
Q28391025 | Current understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease |
Q41552272 | Depletion of regulatory T cells decreases cardiac parasitosis and inflammation in experimental Chagas disease |
Q58846761 | Differential regulation of nitric oxide synthase isoforms in experimental acute chagasic cardiomyopathy |
Q34317894 | Does myoglobin protect Trypanosoma cruzi from the antiparasitic effects of nitric oxide?. |
Q37124936 | Dyskinesis in Chagasic myocardium: centerline analysis of wall motion using cardiac-gated magnetic resonance images of mice |
Q44785726 | Effects of early and late verapamil administration on the development of cardiomyopathy in experimental chronic Trypanosoma cruzi (Brazil strain) infection |
Q26830339 | Endothelin-1 and its role in the pathogenesis of infectious diseases |
Q37392826 | Experimental chemotherapy against Trypanosoma cruzi infection using ruthenium nitric oxide donors |
Q52931841 | Fas-FasL interaction modulates nitric oxide production in Trypanosoma cruzi-infected mice. |
Q35086855 | Imaging the Gastrointestinal Tract of Small Animals |
Q34756581 | Inducible nitric oxide synthase is not essential for control of Trypanosoma cruzi infection in mice |
Q39512381 | Infection of endothelial cells with Trypanosoma cruzi activates NF-kappaB and induces vascular adhesion molecule expression. |
Q54242419 | Lipid Bodies as Sites of Prostaglandin E2 Synthesis During Chagas Disease: Impact in the Parasite Escape Mechanism. |
Q36178423 | Magnetic resonance imaging in experimental Chagas disease: a brief review of the utility of the method for monitoring right ventricular chamber dilatation |
Q28484346 | Mesenchymal bone marrow cell therapy in a mouse model of chagas disease. Where do the cells go? |
Q39265934 | Micro-positron emission tomography in the evaluation of Trypanosoma cruzi-induced heart disease: Comparison with other modalities. |
Q53652238 | Microarray analysis of changes in gene expression in a murine model of chronic chagasic cardiomyopathy. |
Q35002378 | Microarray analysis of the mammalian thromboxane receptor-Trypanosoma cruzi interaction |
Q35180221 | Molecular imaging, biodistribution and efficacy of mesenchymal bone marrow cell therapy in a mouse model of Chagas disease |
Q34163899 | NADPH phagocyte oxidase knockout mice control Trypanosoma cruzi proliferation, but develop circulatory collapse and succumb to infection. |
Q33870393 | New drugs for neglected infectious diseases: Chagas' disease |
Q29617591 | Nitric oxide and the immune response |
Q42152162 | Nitric oxide synthase-2 modulates chemokine production by Trypanosoma cruzi-infected cardiac myocytes |
Q37116835 | Pathology affects different organs in two mouse strains chronically infected by a Trypanosoma cruzi clone: a model for genetic studies of Chagas' disease |
Q28544692 | Pentoxifylline reverses chronic experimental Chagasic cardiomyopathy in association with repositioning of abnormal CD8+ T-cell response |
Q43251669 | Perforin-expressing cytotoxic cells contribute to chronic cardiomyopathy in Trypanosoma cruzi infection |
Q37467729 | Perspectives on Trypanosoma cruzi-induced heart disease (Chagas disease). |
Q36586691 | Recent developments in the interactions between caveolin and pathogens |
Q90169712 | Resolvin D1 Administration is Beneficial in Trypanosoma cruzi Infection |
Q35741974 | Response of adipose tissue to early infection with Trypanosoma cruzi (Brazil strain). |
Q46448473 | Risedronate in the treatment of Murine Chagas' disease |
Q41308213 | Role of NO synthase in the development of Trypanosoma cruzi-induced cardiomyopathy in mice |
Q38878504 | Role of cyclooxygenase-2 in Trypanosoma cruzi survival in the early stages of parasite host-cell interaction |
Q33769435 | Role of endothelin 1 in the pathogenesis of chronic chagasic heart disease |
Q58846210 | Significance of inducible nitric oxide synthase in acute myocarditis caused by Trypanosoma cruzi (Tulahuen strain) |
Q58705710 | The Unsolved Jigsaw Puzzle of the Immune Response in Chagas Disease |
Q58844026 | The benefits of using selenium in the treatment of Chagas disease: prevention of right ventricle chamber dilatation and reversion of Trypanosoma cruzi-induced acute and chronic cardiomyopathy in mice |
Q34240085 | The role of endothelin in the pathogenesis of Chagas' disease |
Q36569125 | The vasculature in chagas disease |
Q36229272 | Thromboxane A2 is a key regulator of pathogenesis during Trypanosoma cruzi infection |
Q41905228 | Trypanosoma cruzi induces changes in cardiac connexin43 expression. |
Q42609696 | Trypanosoma cruzi infection of cultured adipocytes results in an inflammatory phenotype |
Q42735515 | Trypanosoma cruzi infection results in the reduced expression of caveolin-3 in the heart |
Q58844094 | Trypanosoma cruzi infection: do distinct populations cause intestinal motility alteration? |
Q58846862 | Upregulation of adhesion molecules and class I HLA in the myocardium of chronic chagasic cardiomyopathy and heart allograft rejection, but not in dilated cardiomyopathy |
Search more.